We Turn Strategic Awards Into Investor Confidence

We help biotech companies secure non-dilutive capital and connect with strategic investors, so you can extend your runway, hit your milestones, and grow on your terms.

$300K–$20M+ per award
70+ years combined experience
~40% of clients received additional investments from VC & Family Office Network

Why Great Biotech Still Struggles to Access Strategic Capital

Lack of Bandwidth

Your CSO shouldn't be writing grants at midnight. DIY grant applications burn scientific leadership time and still get rejected. You need someone who does this full-time.

Your Science Isn't Generic. Your Strategy Shouldn't Be.

Boilerplate proposals weaken your narrative in front of reviewers and investors. Your data deserves precision, not templates.

Sitting On The Sideline

Your competitor just landed a $20M dollar ARPA-H grant, matched it with VC money, while you are cold pitching to investors. This should have been you.

Validation Is What Moves Capital

99% of pitch decks get ignored. Our clients don't pitch cold. Through our venture and family office network, over 40% of NEXA clients secure follow-on investment backed by grant traction.

Your Partner in Funding & Venture Strategy

We combine deep grant expertise with a venture network to give biotech companies multiple pathways to capital, without unnecessary dilution.

One partner, both tracks

Most firms do grants or investor intros. We do both under one roof - a single funding strategy that combines non-dilutive capital with venture connections, so every milestone moves you forward on both tracks.

Non-Dilutive Capital

We identify, write, and submit grants from NIH, BARDA, DoD, ARPA-H, and foundations, end to end. You keep your equity.

Venture Funding

For companies with strong traction, we facilitate connections to venture capital firms and family offices through our investor network. Over 40% of our clients have gone on to receive venture funding.

How we work with you

A structured process from first conversation to funded milestones.

Step 01
Initial Consultation

We start with a focused conversation about your science, stage, and funding history. No pitch, just an honest assessment of what's possible.

Step 02
Fit & Opportunity Assessment

We map your indication, milestones, and competitive landscape against active federal programs and foundation calls to identify highest-probability opportunities.

Step 03
Customized Funding Strategy

A tailored roadmap covering non-dilutive sources, timelines, and award targets, modeled against your runway and equity position.

Step 04
Proposal Development & Submission

Our team builds reviewer-ready narratives, manages submission logistics, and handles agency communications. You review, we execute.

Step 05
Venture & Follow-on Strategy

With grant traction as your proof point, we introduce you to venture capital firms and family offices in our network. Over 40% of our clients go on to close strategic investment rounds.

Navigating $80B+ Funding Landscape

We match your science and milestones to the right federal programs, in the right order, at the right time.

National Institutes of Health
BARDA
ARPA-H
Department of War
National Science Foundation
ALS Association
Michael J. Fox Foundation
DARPA
Wellcome Trust
CIRM

Leadership

Former NIH program directors, federal grant reviewers, venture capital and biotech strategists.

Common questions

Common questions about working with us.

Non-dilutive funding (federal grants, government programs, and disease foundations) provides capital without giving up equity. A single award can range from $300K to $20M+, extending runway up to 60 months while preserving ownership for founders and early investors.
Most grant consultants help with writing. We go further: strategy, narrative development, submission logistics, and agency communication. We also bring a venture and investor network that creates additional pathways beyond grants. Non-dilutive funding is the cornerstone of our model. We intentionally focus on a select group of companies where our team sees a clear path to unlocking funding, allowing us to dedicate the depth, attention, and expertise required to maximize success.
Biotech and medtech companies with 2–50 employees, typically >$1M raised, pre-IPO, pre-commercial. Any disease area or therapeutic modality. If you have strong science and need structured funding support, we should talk.
We own the heavy lifting: research, writing, project management, and submission coordination. You and your scientific team review and provide input at key milestones. Leadership typically spends 10-20 hours per submission cycle after the initial strategy phase.
NIH (SBIR/STTR, R-series, U-grants), BARDA, DoD, ARPA-H, NSF, disease-focused foundations, and select public-private programs. We match mechanisms to your specific indication, stage, and milestone timeline.
Most grant consultants write proposals. We build funding strategies. Our team includes former NIH Program Directors and federal grant reviewers who know exactly how proposals are scored. We handle everything end to end: strategy, narrative, submission logistics, and agency communication. No boilerplate, no guesswork. If your last consultant didn't understand your science or couldn't explain why you got rejected, that's exactly the gap we fill.
Grant traction is the strongest signal you can send to investors. Once you have federal validation, we introduce you directly to venture capital firms and family offices in our network who invest in biotech at your stage. No cold outreach, no spray-and-pray. Over 40% of our clients have gone on to close venture rounds through these introductions.

Find out what grants match your science

A 30-minute call to assess your fit. You'll leave with clarity on your funding options and a concrete next step. No complexity, no commitment.

After the call you'll know
  • Which grants fit your indication and timeline
  • How much runway you could add without dilution
  • How our venture network can accelerate your next round